Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MEDICATION INFORMATION CAMPAIGN FOR ELDERLY PLANNED FOR 1987

Executive Summary

MEDICATION INFORMATION CAMPAIGN FOR ELDERLY PLANNED FOR 1987 in the autumn by the National Council on Patient Information & Education (NCPIE). With initial funding of $200,000 from the Retirement & Research Foundation, NCPIE is planning to "develop media materials that promote knowledge and enable communication with health care providers about prescription medicines." The campaign will include TV, radio, print ads, and pharmacy and doctor counter cards that will urge older persons to ask for more information about their medications. The campaign will also include a brochure for health professionals urging them to take the initiative in improving communication with older patients. The campaign for next year is an outgrowth of a report prepared by NCPIE under a grant from The Commonwealth Fund. The report discusses 18 priorities "believed to be most important and relevant" in improving drug use in the elderly. The report is entitled "Priorities and Approaches For Improving Prescription Medicine Use By Older Americans." Details on it were presented by NCPIE Project Director Robert Bachman at the group's fifth annual meeting in Washington, D.C. on Nov. 4. Improving the awareness of generic drugs among elderly patients is one of the priority educational strategies addressed by the report. For example, the report notes that one approach to increase awareness of less expensive therapies is to "develop television and radio PSAs [public sevice announcements] and posters to urge consumers to ask physicians and pharmacists about less expensive alternatives with equal therapeutic effect (i.e., generic drugs)." Those media, the report states, should "emphasize that all drugs approved by the FDA meet similar requirements for safety and effectiveness." The report also cites other approaches, not related to generic drug use, that can be used in promoting awareness of cost reduction to older consumers and their caregivers. For example, the report suggests developing "media messages that provide tips for cutting drug costs, such as purchasing in quantity, storing drugs properly to get full value, [and] buying the least expensive form of a drug (e.g., liquid vs. capsules.)" In a foreword to the report, NCPIE explained that the document "is offered as a program planning tool for organizations with an interest in issues related to medication use and as a mandate to serve or represent the older population." NCPIE "developed these ideas in planning a mass media campaign to improve prescription drug use among older people," the report states.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

OM013164

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel